Dream Team Projects

Enabling early cancer detection with lower costs and improved sensitivity from non-invasive genome-wide liquid biopsy tests through novel deep learning analytics and improved chemistry

Co-Director, Molecular Tumor Board, Stanford Cancer Institute (2014 - Present)
(650) 498-9943
Assistant Professor of Genetics and of Computer Science
(650) 723-2353
Specialty Editor, Breast Cancer Advisory Panel, American Society of Clinical Oncology (2016 - Present)
Professor, and Chief, Division of Oncology, Stanford University Medical Center (2013 - Present)
(650) 724-4397
Chief of Breast Surgery, Section of Surgical Oncology (2005 - Present)
(650) 721-5705
Co-Director, Immunodiagnosis Laboratory, Stanford University Medical Center (2003 - Present)
(650) 736-2664

Aim

Develop a novel cfDNA sequencing technology and deep learning analytical framework that achieves state-of-the-art accuracy in distinguishing normal versus pathologic states and tissue-of-origin from clinical samples.

Overarching Objective

A scalable and robust non-invasive assay to detect cancer early, when it is most curable.